Clean Cells opened its capital to ArchiMed to support its growth strategy in the biopharmaceutical sector
The biopharmaceutical services company Clean Cells, specialized in biosafety testing and cell bank and virus seed stock production, has reached... View Article
Emergent BioSolutions and Valneva Report Positive Phase 1 Results for their Vaccine Candidate Against the Zika Virus
EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS GAITHERSBURG, Md. and... View Article
Telix Pharmaceuticals Completes Acquisition of Atlab Pharma
Telix Pharmaceuticals Limited (“Telix”, the “Company”) today announced the completion of the acquisition of Atlab Pharma SAS (“Atlab”). The option... View Article
Samabriva and Affilogic entered into an Option and License Agreement to develop Nanofitin®-conjugated biotherapeutics to treat Lysosomal Storage Disorders
Amiens, France, and Nantes, France, September 10, 2018 – Samabriva and Affilogic jointly announced that they recently entered into an... View Article
In-Cell-Art results with two Top 10 Pharma will be presented at the 16th Annual Discovery on Target on September 25-28 2018 in Boston
In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies named Nanotaxi® designed to unlock the promise of nucleic acids to... View Article
In-Cell-Art, the Institut Pasteur and BioNet-Asia announce the collaborative development of a dengue vaccine candidate successful in preclinical study
Nantes – Paris – France, 19th of June, 2018 – In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies, BioNet-Asia... View Article
Bioregate Forum 2018 #2nd edition
Bioregate Forum is the “must attend” European gathering for key players in the Regenerative Medicine sector: 3 days dedicated to... View Article
Affilogic is financing a proof of concept thanks to the Boost4Health programme
Affilogic,a member of Atlanpole Biotherapies, has received a € 5000 voucher as part of the Boost4Health programme. This support has... View Article
A thymic cell study programme for developing an ambitious transplant strategy
This programme is led by Dr. Matthieu Giraud, a specialist in immunology, genetics and bioinformatics. Having spent a number of... View Article
In-Cell-Art announces a contract with one of top 5 Global Pharmas to discover potential antibodies medicines
Nantes – France, 24 of May , 2018 – In-Cell-Art (ICA), a member of Atlanpole Biotherapies, a biotechnology company specialized in... View Article